Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > COLUMN
COLUMN
-
Maurer's Healthcare Insight (83)
February 19, 2007
-
2006: When the Pendulum Swung P. Reed Maurer
January 8, 2007
-
Maurer's Healthcare Insight (82)／Questions from the Floor P. Reed Maurer
December 18, 2006
-
Maurer's Healthcare Insight (81)
November 20, 2006
-
Maurer's Healthcare Insight (80)
October 23, 2006
-
Maurer's Healthcare Insight (79) Back from the Saddle P. Reed Maurer
September 25, 2006
-
Maurer's Healthcare Insight (78) Infinite Value of a Good Boss P. Reed Maurer
August 28, 2006
-
Maurer's Healthcare Insight (77)
July 24, 2006
-
Maurer's Healthcare Insight (76)
June 26, 2006
-
Maurer's Healthcare Insight (75)
May 29, 2006
-
Maurer's Healthcare Insight (74)
April 10, 2006
-
Maurer's Healthcare Insight (73)
March 13, 2006
-
Maurer's Healthcare Insight (71)
December 19, 2005
-
Maurer's Healthcare Insight (70)
November 28, 2005
-
Maurer's Healthcare Insight(69)
November 14, 2005
-
Maurer's Healthcare Insight (68)
October 17, 2005
-
Maurer's Healthcare Insight (67)
September 26, 2005
-
Maurer's Healthcare Insight (66)
August 8, 2005
-
Maurer's Healthcare Insight (65)
July 11, 2005
-
Maurer's Healthcare Insight (64)
June 13, 2005
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…